title: C-reactive protein is a potential prognostic factor for metastatic gastric cancer.
abstract: OBJECTIVE
  C-reactive protein (CRP) has been associated with the development of many carcinomas, but the significance of CRP remains unclear for metastatic gastric cancer (MGC).
  
  
  METHODS
  Sixty one patients who received S-1 plus cisplatin for MGC were retrospectively identified and categorized into two groups depending on the serum CRP level before chemotherapy.
  
  
  RESULTS
  Overall survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 292 days versus 451 days; p=0.0004). Moreover, progression-free survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 115 days versus 188 days; p=0.0010). In a multivariate analysis, serum CRP level before chemotherapy was an independent prognostic factor for MGC (hazard ratio 4.20 [95% CI, 1.66 to 10.64] p=0.002).
  
  
  CONCLUSIONS
  Serum CRP level before chemotherapy might be a potential prognostic factor for MGC.
authors.affiliation: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. tshimura@med.nagoya-cu.ac.jp
authors.forename: Takaya
authors.initials: T
authors.lastname: Shimura
authors.forename: Mika
authors.initials: M
authors.lastname: Kitagawa
authors.forename: Tomonori
authors.initials: T
authors.lastname: Yamada
authors.forename: Masahide
authors.initials: M
authors.lastname: Ebi
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Mizoshita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tanida
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kataoka
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kamiya
authors.forename: Takashi
authors.initials: T
authors.lastname: Joh
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000097:blood* / Q000188:drug therapy*; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002097:C-Reactive Protein; D002945:Cisplatin